October 16th 2024, 1:00pm
An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.
October 14th 2024, 4:29pm
Panelists discuss how the PSA test is conducted and interpreted, and clarify the definitions of high-risk and advanced prostate cancer types, including their implications for prognosis and subsequent treatment decisions.
October 14th 2024, 4:22pm
Panelists discuss how identifying the right candidates for prostate cancer screening and understanding the role of routine screenings versus symptom-driven assessments are essential for early diagnosis and effective management.
October 14th 2024, 3:00pm
An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.
October 12th 2024, 6:00pm
The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.
October 7th 2024, 9:00pm
For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.
September 21st 2024, 2:00pm
At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.
September 20th 2024, 12:59pm
The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.
September 20th 2024, 12:57pm
The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during and after treatment.
September 16th 2024, 3:00pm
At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.
“Chillin’ Out” and Finding Our Cancer Community
Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
Illuminating Compassion in Cancer Care